Betting on immunotherapy for melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-08-11

AUTHORS

Mario Sznol

ABSTRACT

Immunotherapy is an effective treatment option for a small percentage of patients with advanced melanoma or at high risk for recurrence after resection of the primary tumor. However, a long period of unsuccessful immune modulation trials involving new cytokines, antibodies, cancer vaccines, adoptive immunotherapy, and combinations generated doubts that benefit could be extended to a larger group of patients. Renewed optimism for the therapeutic potential of immune therapy is currently driven by key advances in tumor immunobiology, including the potential to manipulate and disrupt immune activation checkpoints and tumor defense mechanisms; newer approaches to antigen presentation for immune activation; refinements to procedures for antigen-specific T-cell expansions in vitro and preparative regimens to support their expansion and activity in vivo; gene transfer to alter lymphocyte specificity and function; and the potential for discovery of improved predictive biomarkers to select patients for individual treatments. Proof of concept is provided by durable remissions observed in patients with advanced melanoma enrolled in clinical trials of anti-CTLA-4 and in new studies of adoptively transferred tumor antigen-specific lymphocytes combined with lymphocyte ablation conditioning regimens. Many agents now being developed are predicted to produce broader, more potent, and more effective antitumor immune responses. More... »

PAGES

397-404

References to SciGraph publications

  • 2008-04. Adoptive cell transfer: a clinical path to effective cancer immunotherapy in NATURE REVIEWS CANCER
  • 2007-01-01. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment in NATURE REVIEWS IMMUNOLOGY
  • 2007-11-18. T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection in NATURE MEDICINE
  • 2007-02. Immunostimulatory monoclonal antibodies for cancer therapy in NATURE REVIEWS CANCER
  • 2008-01-06. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy in NATURE MEDICINE
  • 2004-09-01. Cancer immunotherapy: moving beyond current vaccines in NATURE MEDICINE
  • 2005-10-21. Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study in ANNALS OF SURGICAL ONCOLOGY
  • 2002-10. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation in NATURE
  • 2008-09-16. TGF-β and Regulatory T Cell in Immunity and Autoimmunity in JOURNAL OF CLINICAL IMMUNOLOGY
  • 1999-06. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients in NATURE MEDICINE
  • 2006-02-17. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2009-02-06. Ipilimumab: controversies in its development, utility and autoimmune adverse events in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2002-06-24. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion in NATURE MEDICINE
  • 2002-09. Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion in NATURE MEDICINE
  • 2006-02-12. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11912-009-0053-z

    DOI

    http://dx.doi.org/10.1007/s11912-009-0053-z

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1001119476

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/19679015


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antigens, CD", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "CTLA-4 Antigen", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ipilimumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Yale Cancer Center, 333 Cedar Street, FMP #126, 06525, New Haven, CT, USA", 
              "id": "http://www.grid.ac/institutes/grid.433818.5", 
              "name": [
                "Yale Cancer Center, 333 Cedar Street, FMP #126, 06525, New Haven, CT, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sznol", 
            "givenName": "Mario", 
            "id": "sg:person.0706626451.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nm1676", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018179674", 
              "https://doi.org/10.1038/nm1676"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10875-008-9251-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010499655", 
              "https://doi.org/10.1007/s10875-008-9251-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/9525", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029975164", 
              "https://doi.org/10.1038/9525"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1100", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001965372", 
              "https://doi.org/10.1038/nm1100"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1359", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021773024", 
              "https://doi.org/10.1038/nm1359"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm730", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043110107", 
              "https://doi.org/10.1038/nm730"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0902-1039c", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038547603", 
              "https://doi.org/10.1038/nm0902-1039c"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1699", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018225414", 
              "https://doi.org/10.1038/nm1699"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri1995", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052092567", 
              "https://doi.org/10.1038/nri1995"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature01112", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006224635", 
              "https://doi.org/10.1038/nature01112"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-006-0141-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020368307", 
              "https://doi.org/10.1007/s00262-006-0141-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2051", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015813726", 
              "https://doi.org/10.1038/nrc2051"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/aso.2005.03.536", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024972195", 
              "https://doi.org/10.1245/aso.2005.03.536"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-008-0653-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043129240", 
              "https://doi.org/10.1007/s00262-008-0653-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc2355", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050199541", 
              "https://doi.org/10.1038/nrc2355"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2009-08-11", 
        "datePublishedReg": "2009-08-11", 
        "description": "Immunotherapy is an effective treatment option for a small percentage of patients with advanced melanoma or at high risk for recurrence after resection of the primary tumor. However, a long period of unsuccessful immune modulation trials involving new cytokines, antibodies, cancer vaccines, adoptive immunotherapy, and combinations generated doubts that benefit could be extended to a larger group of patients. Renewed optimism for the therapeutic potential of immune therapy is currently driven by key advances in tumor immunobiology, including the potential to manipulate and disrupt immune activation checkpoints and tumor defense mechanisms; newer approaches to antigen presentation for immune activation; refinements to procedures for antigen-specific T-cell expansions in vitro and preparative regimens to support their expansion and activity in vivo; gene transfer to alter lymphocyte specificity and function; and the potential for discovery of improved predictive biomarkers to select patients for individual treatments. Proof of concept is provided by durable remissions observed in patients with advanced melanoma enrolled in clinical trials of anti-CTLA-4 and in new studies of adoptively transferred tumor antigen-specific lymphocytes combined with lymphocyte ablation conditioning regimens. Many agents now being developed are predicted to produce broader, more potent, and more effective antitumor immune responses.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s11912-009-0053-z", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1021174", 
            "issn": [
              "1523-3790", 
              "1534-6269"
            ], 
            "name": "Current Oncology Reports", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "11"
          }
        ], 
        "keywords": [
          "advanced melanoma", 
          "antigen-specific T cell expansion", 
          "effective antitumor immune response", 
          "antitumor immune response", 
          "effective treatment option", 
          "T cell expansion", 
          "antigen-specific lymphocytes", 
          "tumor defense mechanisms", 
          "preparative regimens", 
          "durable remissions", 
          "conditioning regimens", 
          "adoptive immunotherapy", 
          "immune therapy", 
          "cancer vaccines", 
          "immune activation", 
          "treatment options", 
          "primary tumor", 
          "tumor immunobiology", 
          "predictive biomarkers", 
          "clinical trials", 
          "antigen presentation", 
          "immune response", 
          "high risk", 
          "new cytokine", 
          "patients", 
          "therapeutic potential", 
          "immunotherapy", 
          "lymphocyte specificity", 
          "melanoma", 
          "individual treatment", 
          "regimens", 
          "trials", 
          "small percentage", 
          "defense mechanisms", 
          "new studies", 
          "large group", 
          "remission", 
          "resection", 
          "recurrence", 
          "gene transfer", 
          "cytokines", 
          "immunobiology", 
          "lymphocytes", 
          "vaccine", 
          "therapy", 
          "tumors", 
          "biomarkers", 
          "antibodies", 
          "treatment", 
          "risk", 
          "vivo", 
          "long period", 
          "presentation", 
          "activation", 
          "group", 
          "options", 
          "agents", 
          "specificity", 
          "percentage", 
          "key advances", 
          "response", 
          "period", 
          "potential", 
          "activity", 
          "study", 
          "benefits", 
          "checkpoint", 
          "procedure", 
          "proof of concept", 
          "mechanism", 
          "advances", 
          "optimism", 
          "combination", 
          "function", 
          "discovery", 
          "doubt", 
          "expansion", 
          "new approach", 
          "approach", 
          "refinement", 
          "transfer", 
          "proof", 
          "concept"
        ], 
        "name": "Betting on immunotherapy for melanoma", 
        "pagination": "397-404", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1001119476"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11912-009-0053-z"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "19679015"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11912-009-0053-z", 
          "https://app.dimensions.ai/details/publication/pub.1001119476"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:53", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_481.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s11912-009-0053-z"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11912-009-0053-z'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11912-009-0053-z'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11912-009-0053-z'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11912-009-0053-z'


     

    This table displays all metadata directly associated to this object as RDF triples.

    240 TRIPLES      21 PREDICATES      132 URIs      108 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11912-009-0053-z schema:about N09ac53ac0b4140c6bf923a2e32590fbf
    2 N74d44b03b6f74a9caef0c3193ad8fe8c
    3 N82ca8567b08c436b805a3476107b9f7c
    4 Na669ea8b7424458a841014b7185b3902
    5 Nb711d88fd3a94f569602980bdadefeb9
    6 Ndc0aabd63fe04212a398c471208f7093
    7 Nf173ff5dc25f4c2ba090d179e5446b3e
    8 Nfb8d7b5cd6da42fa9ea1f59ba59fbde7
    9 anzsrc-for:11
    10 anzsrc-for:1107
    11 anzsrc-for:1112
    12 schema:author N9b8a182605c9498d8d5a804dba17c13f
    13 schema:citation sg:pub.10.1007/s00262-006-0141-y
    14 sg:pub.10.1007/s00262-008-0653-8
    15 sg:pub.10.1007/s10875-008-9251-y
    16 sg:pub.10.1038/9525
    17 sg:pub.10.1038/nature01112
    18 sg:pub.10.1038/nm0902-1039c
    19 sg:pub.10.1038/nm1100
    20 sg:pub.10.1038/nm1359
    21 sg:pub.10.1038/nm1676
    22 sg:pub.10.1038/nm1699
    23 sg:pub.10.1038/nm730
    24 sg:pub.10.1038/nrc2051
    25 sg:pub.10.1038/nrc2355
    26 sg:pub.10.1038/nri1995
    27 sg:pub.10.1245/aso.2005.03.536
    28 schema:datePublished 2009-08-11
    29 schema:datePublishedReg 2009-08-11
    30 schema:description Immunotherapy is an effective treatment option for a small percentage of patients with advanced melanoma or at high risk for recurrence after resection of the primary tumor. However, a long period of unsuccessful immune modulation trials involving new cytokines, antibodies, cancer vaccines, adoptive immunotherapy, and combinations generated doubts that benefit could be extended to a larger group of patients. Renewed optimism for the therapeutic potential of immune therapy is currently driven by key advances in tumor immunobiology, including the potential to manipulate and disrupt immune activation checkpoints and tumor defense mechanisms; newer approaches to antigen presentation for immune activation; refinements to procedures for antigen-specific T-cell expansions in vitro and preparative regimens to support their expansion and activity in vivo; gene transfer to alter lymphocyte specificity and function; and the potential for discovery of improved predictive biomarkers to select patients for individual treatments. Proof of concept is provided by durable remissions observed in patients with advanced melanoma enrolled in clinical trials of anti-CTLA-4 and in new studies of adoptively transferred tumor antigen-specific lymphocytes combined with lymphocyte ablation conditioning regimens. Many agents now being developed are predicted to produce broader, more potent, and more effective antitumor immune responses.
    31 schema:genre article
    32 schema:isAccessibleForFree false
    33 schema:isPartOf Na90d60ecd25f46c291fda247ef4c4bae
    34 Nf97ba7ae0b0c4d679889d962e53cb4c2
    35 sg:journal.1021174
    36 schema:keywords T cell expansion
    37 activation
    38 activity
    39 adoptive immunotherapy
    40 advanced melanoma
    41 advances
    42 agents
    43 antibodies
    44 antigen presentation
    45 antigen-specific T cell expansion
    46 antigen-specific lymphocytes
    47 antitumor immune response
    48 approach
    49 benefits
    50 biomarkers
    51 cancer vaccines
    52 checkpoint
    53 clinical trials
    54 combination
    55 concept
    56 conditioning regimens
    57 cytokines
    58 defense mechanisms
    59 discovery
    60 doubt
    61 durable remissions
    62 effective antitumor immune response
    63 effective treatment option
    64 expansion
    65 function
    66 gene transfer
    67 group
    68 high risk
    69 immune activation
    70 immune response
    71 immune therapy
    72 immunobiology
    73 immunotherapy
    74 individual treatment
    75 key advances
    76 large group
    77 long period
    78 lymphocyte specificity
    79 lymphocytes
    80 mechanism
    81 melanoma
    82 new approach
    83 new cytokine
    84 new studies
    85 optimism
    86 options
    87 patients
    88 percentage
    89 period
    90 potential
    91 predictive biomarkers
    92 preparative regimens
    93 presentation
    94 primary tumor
    95 procedure
    96 proof
    97 proof of concept
    98 recurrence
    99 refinement
    100 regimens
    101 remission
    102 resection
    103 response
    104 risk
    105 small percentage
    106 specificity
    107 study
    108 therapeutic potential
    109 therapy
    110 transfer
    111 treatment
    112 treatment options
    113 trials
    114 tumor defense mechanisms
    115 tumor immunobiology
    116 tumors
    117 vaccine
    118 vivo
    119 schema:name Betting on immunotherapy for melanoma
    120 schema:pagination 397-404
    121 schema:productId N0f275208701145e082009a02645594f3
    122 N2ed4dffa50e2403c9f5988a68b410a6f
    123 Nb10d4ef4f687401188626227a418832e
    124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001119476
    125 https://doi.org/10.1007/s11912-009-0053-z
    126 schema:sdDatePublished 2022-09-02T15:53
    127 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    128 schema:sdPublisher N4e0efee6f0de4ec7ab9d6b6309809a53
    129 schema:url https://doi.org/10.1007/s11912-009-0053-z
    130 sgo:license sg:explorer/license/
    131 sgo:sdDataset articles
    132 rdf:type schema:ScholarlyArticle
    133 N09ac53ac0b4140c6bf923a2e32590fbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Melanoma
    135 rdf:type schema:DefinedTerm
    136 N0f275208701145e082009a02645594f3 schema:name pubmed_id
    137 schema:value 19679015
    138 rdf:type schema:PropertyValue
    139 N2ed4dffa50e2403c9f5988a68b410a6f schema:name dimensions_id
    140 schema:value pub.1001119476
    141 rdf:type schema:PropertyValue
    142 N4e0efee6f0de4ec7ab9d6b6309809a53 schema:name Springer Nature - SN SciGraph project
    143 rdf:type schema:Organization
    144 N74d44b03b6f74a9caef0c3193ad8fe8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Antibodies, Monoclonal
    146 rdf:type schema:DefinedTerm
    147 N82ca8567b08c436b805a3476107b9f7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Antigens, CD
    149 rdf:type schema:DefinedTerm
    150 N9b8a182605c9498d8d5a804dba17c13f rdf:first sg:person.0706626451.72
    151 rdf:rest rdf:nil
    152 Na669ea8b7424458a841014b7185b3902 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Treatment Outcome
    154 rdf:type schema:DefinedTerm
    155 Na90d60ecd25f46c291fda247ef4c4bae schema:volumeNumber 11
    156 rdf:type schema:PublicationVolume
    157 Nb10d4ef4f687401188626227a418832e schema:name doi
    158 schema:value 10.1007/s11912-009-0053-z
    159 rdf:type schema:PropertyValue
    160 Nb711d88fd3a94f569602980bdadefeb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Immunotherapy
    162 rdf:type schema:DefinedTerm
    163 Ndc0aabd63fe04212a398c471208f7093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Humans
    165 rdf:type schema:DefinedTerm
    166 Nf173ff5dc25f4c2ba090d179e5446b3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    167 schema:name CTLA-4 Antigen
    168 rdf:type schema:DefinedTerm
    169 Nf97ba7ae0b0c4d679889d962e53cb4c2 schema:issueNumber 5
    170 rdf:type schema:PublicationIssue
    171 Nfb8d7b5cd6da42fa9ea1f59ba59fbde7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Ipilimumab
    173 rdf:type schema:DefinedTerm
    174 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    175 schema:name Medical and Health Sciences
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Immunology
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Oncology and Carcinogenesis
    182 rdf:type schema:DefinedTerm
    183 sg:journal.1021174 schema:issn 1523-3790
    184 1534-6269
    185 schema:name Current Oncology Reports
    186 schema:publisher Springer Nature
    187 rdf:type schema:Periodical
    188 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.433818.5
    189 schema:familyName Sznol
    190 schema:givenName Mario
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
    192 rdf:type schema:Person
    193 sg:pub.10.1007/s00262-006-0141-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1020368307
    194 https://doi.org/10.1007/s00262-006-0141-y
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1007/s00262-008-0653-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043129240
    197 https://doi.org/10.1007/s00262-008-0653-8
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1007/s10875-008-9251-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010499655
    200 https://doi.org/10.1007/s10875-008-9251-y
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1038/9525 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029975164
    203 https://doi.org/10.1038/9525
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1038/nature01112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006224635
    206 https://doi.org/10.1038/nature01112
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1038/nm0902-1039c schema:sameAs https://app.dimensions.ai/details/publication/pub.1038547603
    209 https://doi.org/10.1038/nm0902-1039c
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1038/nm1100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001965372
    212 https://doi.org/10.1038/nm1100
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1038/nm1359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021773024
    215 https://doi.org/10.1038/nm1359
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1038/nm1676 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018179674
    218 https://doi.org/10.1038/nm1676
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1038/nm1699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018225414
    221 https://doi.org/10.1038/nm1699
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1038/nm730 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043110107
    224 https://doi.org/10.1038/nm730
    225 rdf:type schema:CreativeWork
    226 sg:pub.10.1038/nrc2051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015813726
    227 https://doi.org/10.1038/nrc2051
    228 rdf:type schema:CreativeWork
    229 sg:pub.10.1038/nrc2355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050199541
    230 https://doi.org/10.1038/nrc2355
    231 rdf:type schema:CreativeWork
    232 sg:pub.10.1038/nri1995 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052092567
    233 https://doi.org/10.1038/nri1995
    234 rdf:type schema:CreativeWork
    235 sg:pub.10.1245/aso.2005.03.536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024972195
    236 https://doi.org/10.1245/aso.2005.03.536
    237 rdf:type schema:CreativeWork
    238 grid-institutes:grid.433818.5 schema:alternateName Yale Cancer Center, 333 Cedar Street, FMP #126, 06525, New Haven, CT, USA
    239 schema:name Yale Cancer Center, 333 Cedar Street, FMP #126, 06525, New Haven, CT, USA
    240 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...